Aravive (ARAV) Competitors $0.04 0.00 (0.00%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsSustainabilityTrends ARAV vs. PMCB, APLM, TSBX, BCLI, JAGX, MBIO, BLRX, CDT, PHXM, and AWHShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include PharmaCyte Biotech (PMCB), Apollomics (APLM), Turnstone Biologics (TSBX), Brainstorm Cell Therapeutics (BCLI), Jaguar Health (JAGX), Mustang Bio (MBIO), BioLineRx (BLRX), Conduit Pharmaceuticals (CDT), PHAXIAM Therapeutics (PHXM), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry. Aravive vs. PharmaCyte Biotech Apollomics Turnstone Biologics Brainstorm Cell Therapeutics Jaguar Health Mustang Bio BioLineRx Conduit Pharmaceuticals PHAXIAM Therapeutics Aspira Women's Health Aravive (NASDAQ:ARAV) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking. Do institutionals & insiders hold more shares of ARAV or PMCB? 35.8% of Aravive shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Comparatively, 7.3% of PharmaCyte Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to ARAV or PMCB? In the previous week, PharmaCyte Biotech's average media sentiment score of 1.00 beat Aravive's score of 0.00 indicating that PharmaCyte Biotech is being referred to more favorably in the news media. Company Overall Sentiment Aravive Neutral PharmaCyte Biotech Positive Which has higher earnings & valuation, ARAV or PMCB? PharmaCyte Biotech has lower revenue, but higher earnings than Aravive. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAravive$9.14M0.32-$76.32MN/AN/APharmaCyte BiotechN/AN/A$330K$0.533.24 Is ARAV or PMCB more profitable? PharmaCyte Biotech's return on equity of 0.76% beat Aravive's return on equity.Company Net Margins Return on Equity Return on Assets AraviveN/A N/A N/A PharmaCyte Biotech N/A 0.76%0.45% Does the MarketBeat Community prefer ARAV or PMCB? Aravive received 104 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformAraviveOutperform Votes10462.28% Underperform Votes6337.72% PharmaCyte BiotechN/AN/A SummaryAravive and PharmaCyte Biotech tied by winning 4 of the 8 factors compared between the two stocks. Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAravivePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.52B$5.34B$9.11BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A4.4457.4913.22Price / Sales0.32310.281,275.6876.05Price / CashN/A22.6336.6032.90Price / BookN/A4.964.874.58Net Income-$76.32M$154.90M$118.05M$224.84M7 Day PerformanceN/A1.38%1.50%2.37%1 Month PerformanceN/A0.44%2.55%4.40%1 Year PerformanceN/A3.11%25.83%20.11% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAraviveN/A$0.04flatN/AN/A$2.95M$9.14M0.0020High Trading VolumePMCBPharmaCyte BiotechN/A$1.52flatN/A-28.7%$11.67MN/A2.872APLMApollomics2.3923 of 5 stars$10.72+1.7%$200.00+1,766.5%-89.3%$11.65M$1.22M0.0045TSBXTurnstone Biologics3.0592 of 5 stars$0.50+4.1%$2.13+325.0%-77.0%$11.56M$19.31M-0.1582News CoverageBCLIBrainstorm Cell Therapeutics4.5373 of 5 stars$2.02-0.2%$30.00+1,388.8%-55.1%$11.49MN/A-0.4240Analyst UpgradeNews CoverageGap UpJAGXJaguar Health0.5596 of 5 stars$0.95-5.0%N/A-86.1%$11.21M$10.48M0.0050MBIOMustang Bio2.6054 of 5 stars$0.22-12.4%$2.00+789.3%-91.8%$10.75MN/A-0.14100Stock SplitGap DownBLRXBioLineRx2.9691 of 5 stars$0.13-6.2%$9.00+6,616.4%-92.5%$10.71M$21.99M-0.6140Analyst ForecastStock SplitNews CoverageGap UpCDTConduit PharmaceuticalsN/A$0.10-15.8%N/A-97.5%$10.68MN/A0.003PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AWHAspira Women's Health2.4734 of 5 stars$0.62-1.4%$4.40+607.4%-88.8%$10.35M$8.96M-0.52110Positive NewsGap Up Related Companies and Tools Related Companies PMCB Competitors APLM Competitors TSBX Competitors BCLI Competitors JAGX Competitors MBIO Competitors BLRX Competitors CDT Competitors PHXM Competitors AWH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARAV) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
